Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$--
EBITDA
$--
Net Profit
$--
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Seelos Therapeutics, Inc (SEELQ)
| -99.78 | 0.00 | -99.85 | -100.00 | -99.45 | -95.14 | -88.25 |
|
BSE Sensex*
| 1.48 | 4.01 | 3.03 | 8.65 | 11.66 | 20.20 | 11.03 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an... intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Address: 300 Park Avenue, New York, NY, United States, 10022 Read more
CEO, Founder, President & Chairman
Dr. Raj Mehra J.D., Ph.D.
Chief Financial Officer
Mr. Michael J. Golembiewski
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Seelos Therapeutics, Inc (SEELQ) is $0.00 (NASDAQ) as of 16-Apr-2025 16:00 EDT. Seelos Therapeutics, Inc (SEELQ) has given a return of -99.45% in the last 3 years.
Seelos Therapeutics, Inc (SEELQ) has a market capitalisation of -- as on 16-Apr-2025. As per Value Research classification, it is a company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Seelos Therapeutics, Inc (SEELQ) and enter the required number of quantities and click on buy to purchase the shares of Seelos Therapeutics, Inc (SEELQ).
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Address: 300 Park Avenue, New York, NY, United States, 10022
The CEO & director of Dr. Raj Mehra J.D., Ph.D.. is Seelos Therapeutics, Inc (SEELQ), and CFO & Sr. VP is Mr. Michael J. Golembiewski.
There is no promoter pledging in Seelos Therapeutics, Inc (SEELQ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Seelos Therapeutics, Inc. (SEELQ) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Seelos Therapeutics, Inc (SEELQ) was $0 Mln.
